An experimental adenoviral vector vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

ChAd-SARS-CoV-2-S is an experimental vaccine based on chimpanzee adenovirus-36 vector (replication-incompetent) carrying a codon optimized sequence of SARS-CoV-2 S protein as an immunogen (Hassan et al., 2020).


Supporting references

Link Tested on Impact factor Notes Publication date
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Viral vector Animal model In vitro Mixed substance
B6.Cg-Tg(K18-ACE2)2Prlmn/J mice; BALB/c mice; C57BL/6J mice; Vero E6 cells; Vero-Furin cells; SARS-CoV-2 (strain 2019 n-CoV/USA_WA1/2020) 38.64

Upon intranasal administration, the vaccine induced anti-SARS-CoV-2 S/RBD protein IgA ang IgG neutralizing antibodies, T cell response and almost completely protected mice expressing human ACE2 receptor from SARS-CoV-2 infection. No chemokine/cytokine mRNA in lung homogenates was detected in the vaccinated mice. Intramuscular administration was not as efficient.

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
Spike protein Viral vector Animal model Mixed substance
Rhesus macaques; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020

A single-dose vaccination induced (as assessed after 1 month) anti-Spike (IgG/IgA) antibodies, anti-RBD (IgG) antibodies, neutralizing antibodies, and T cell responses in rhesus macaques, which correlated with protection of the animals in a nasal/bronchial SARS-CoV-2 challenge. A significant reduction in lung viral loads and lung pathology compared to control was observed.


AI-suggested references